The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.Get Started for Free
Peter Welford is an analyst at Jefferies. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 07/22/2024
| Buy Now | Get Alert | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 07/02/2024 | NVS | Buy Now | Novartis | $108.03 | 13.39% | $121 → $122.5 | Maintains | Buy | Get Alert |
| 07/02/2024 | GSK | Buy Now | GSK | $39.40 | 34.52% | $52.5 → $53 | Maintains | Buy | Get Alert |
| 01/03/2024 | AZN | Buy Now | AstraZeneca | $79.35 | — | — | Downgrade | Buy → Hold | Get Alert |
| 01/03/2024 | GSK | Buy Now | GSK | $39.40 | 21.83% | $38.5 → $48 | Upgrade | Hold → Buy | Get Alert |
| 09/25/2023 | AZN | Buy Now | AstraZeneca | $79.35 | 0.82% | $66.5 → $80 | Upgrade | Hold → Buy | Get Alert |
| 01/23/2023 | GLPG | Buy Now | Galapagos | $26.31 | 79.4% | $49 → $47.2 | Upgrade | Underperform → Hold | Get Alert |
| 12/07/2021 | AZN | Buy Now | AstraZeneca | $79.35 | — | — | Downgrade | Buy → Hold | Get Alert |
